secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000929638-25-002927
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents Q2 revenue $9.6M (+9% YoY); net income $1.9M but adjusted loss widens
--------------------------------------------------------------------------------

- Revenue $9.6M, up 9% YoY (4% constant currency); Germany sales up 22% YoY and sequentially.
- Net income $1.9M ($0.03/share) vs net loss $4.3M in Q2 2024; adjusted net loss $3.7M vs $2.8M.
- Adjusted EBITDA loss $2.6M vs $2.2M in Q2 2024; cash $11.7M at quarter end.
- FDA appeal for DrugSorb-ATR held in July; administrative review expected by end of August 2025.
- Health Canada reconsideration filed; will proceed after FDA decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000092963825002927/0000929638-25-002927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000092963825002927/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-25-002927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer